Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory Syndrome Coronavirus

Huang, Xinyu; Meng, Li; Xu, Yurui; Zhang, Jikang; Meng, Xiaomei; An, Xueying; Sun, Lei; Guo, Leilei; Xue, Song; Ge, Junliang; Chen, Jiao; Luo, Yadong; Wu, Heming; Zhang, Yu; Jiang, Qing; Ning, Xinghai

doi:10.1021/acsami.9b04240

Cited by 88 publications

(89 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The * for P21S10 refers to the position of the residue used to form the staple. (Xia et al, 2020(Xia et al, , 2019 T. Tang, et al Antiviral Research 178 (2020) 104792 behavioral abnormalities between PIH-AuNR treated and control groups (Huang et al, 2019). An alternative strategy of using peptides to target non-HR regions has also been studied, albeit to a limited degree.…”

Section: Sars-cov and Mers-cov Current Antifusogenicsmentioning

confidence: 99%

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

et al. 2020

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2, and also against other pathogenic coronaviruses (CoV) that have emerged in the past or might appear in future. Researchers are therefore focusing on steps in the CoV replication cycle that may be vulnerable to inhibition by broad-spectrum or specific antiviral agents. The conserved nature of the fusion domain and mechanism across the CoV family make it a valuable target to elucidate and develop pan-CoV therapeutics. In this article, we review the role of the CoV spike protein in mediating fusion of the viral and host cell membranes, summarizing the results of research on SARS-CoV, MERS-CoV, and recent peer-reviewed studies of SARS-CoV-2, and suggest that the fusion mechanism be investigated as a potential antiviral target. We also provide a supplemental file containing background information on the biology, epidemiology, and clinical features of all human-infecting coronaviruses, along with a phylogenetic tree of these coronaviruses.

show abstract

Section: Sars-cov and Mers-cov Current Antifusogenicsmentioning

confidence: 99%

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interestingly, the inhibitory effect of PIH has been further enhanced 10-fold by formulating the gold nanorod complex. Additionally, the nano-formula has shown improved pharmacokinetic profile and biocompatibility on both levels, in vitro and in vivo [139,140].…”

Section: Resveratrolmentioning

confidence: 99%

Targeting arachidonic acid–related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles

Shoieb,

El-Ghiaty,

El-Kadi

2020

emergent mater.

View full text Add to dashboard Cite

In March 2020, The World Health Organization (WHO) has declared that the coronavirus disease 2019 (COVID-19) is characterized as a global pandemic. As of September 2020, infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to 213 countries and territories around the world, affected more than 31.5 million people, and caused more than 970,000 deaths worldwide. Although COVID-19 is a respiratory illness that mainly targets the lungs, it is currently well established that it is a multifactorial disease that affects other extra-pulmonary systems and strongly associated with a detrimental inflammatory response. Evidence has shown that SARS-CoV-2 causes perturbation in the arachidonic acid (AA) metabolic pathways; this disruption could lead to an imbalance between the pro-inflammatory metabolites of AA including mid-chain HETEs and terminal HETE (20-HETE) and the anti-inflammatory metabolites such as EETs and subterminal HETEs. Therefore, we propose novel therapeutic strategies to modulate the level of endogenous anti-inflammatory metabolites of AA and induce the patient’s endogenous resolution mechanisms that will ameliorate the virus-associated systemic inflammation and enhance the primary outcomes in COVID-19 patients. Also, we propose that using nanoencapsulation of AA and its associated metabolites will contribute to the development of safer and more efficacious treatments for the management of COVID-19.

show abstract

“…Mainly, the inhibitory influences of peptide pregnancy-prompted hypertension have been accelerated 10-fold by generation of a gold nanorod complex. Additionally, this complex showed improved biocompatibility and metabolic strength, both in vivo and in vitro, thus successfully forestalling sheath merging prompted by MERS-CoV [61].…”

Section: Nanotechnology Against Viral Infections With Focus On Covsmentioning

confidence: 95%

“…In one investigation, heptad repeat 1 (HR1) peptide inhibitors were examined for inhibiting HR1/HR2-mediated sheath merging among MERS-CoV and host cells, the main conduit for host infections induced by MERS-CoV [61]. Mainly, the inhibitory influences of peptide pregnancy-prompted hypertension have been accelerated 10-fold by generation of a gold nanorod complex.…”

Section: Nanotechnology Against Viral Infections With Focus On Covsmentioning

confidence: 99%

Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses

et al. 2020

View full text Add to dashboard Cite

Viral infections have recently emerged not only as a health threat to people but rapidly became the cause of universal fatality on a large scale. Nanomaterials comprising functionalized nanoparticles (NPs) and quantum dots and nanotechnology-associated innovative detection methods, vaccine design, and nanodrug production have shown immense promise for interfacing with pathogenic viruses and restricting their entrance into cells. These viruses have been scrutinized using rapid diagnostic detection and therapeutic interventional options against the caused infections including vaccine development for prevention and control. Coronaviruses, namely SARS-CoV, MERS-CoV, and SARS-CoV-2, have endangered human life, and the COVID-19 (caused by SARS-CoV-2) outbreak has become a perilous challenge to public health globally with huge accompanying morbidity rates. Thus, it is imperative to expedite the drug and vaccine development efforts that would help mitigate this pandemic. In this regard, smart and innovative nano-based technologies and approaches encompassing applications of green nanomedicine, bio-inspired methods, multifunctional bioengineered nanomaterials, and biomimetic drug delivery systems/carriers can help resolve the critical issues regarding detection, prevention, and treatment of viral infections. This perspective review expounds recent nanoscience advancements for the detection and treatment of viral infections with focus on coronaviruses and encompasses nano-based formulations and delivery platforms, nanovaccines, and promising methods for clinical diagnosis, especially regarding SARS-CoV-2.

show abstract

Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory Syndrome Coronavirus

Cited by 88 publications

References 32 publications

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Targeting arachidonic acid–related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles

Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses

Contact Info

Product

Resources

About